Key Points
- To review the clinical rationale and therapeutic efficacy of combining dihydropyridine calcium channel blockers with angiotensin receptor blockers in managing hypertension.
- Reviewed clinical trials examining dihydropyridine calcium channel blocker and angiotensin receptor blocker combinations, including amlodipine paired with olmesartan medoxomil or valsartan.
- Evaluated the complementary pharmacological mechanisms, blood pressure control rates, organ-protection profiles, and adverse event frequencies.
- Combining calcium channel blockers and angiotensin receptor blockers provides additive blood pressure lowering with lower incidences of adverse events compared to monotherapy.
- Angiotensin receptor blockers confer renal and stroke protection with placebo-like tolerability, while calcium channel blockers reduce stroke risk and alleviate cardiac ischemia and angina.
Structured PICO
PPopulationPatients with hypertension
IInterventionCalcium channel blocker (CCB) and angiotensin receptor blocker (ARB) combination therapy (specifically amlodipine combined with olmesartan medoxomil or valsartan)
CCB/ARB combination therapy is a rational strategy for hypertension management, offering additive blood pressure reduction and favorable tolerability.